小檗堿是從黃連等植物中提取的一種異喹啉類生物堿,作為傳統(tǒng)的抗炎、抑菌藥物在臨床應(yīng)用已久。近年來研究發(fā)現(xiàn)其具有調(diào)脂作用,可通過調(diào)節(jié)腸道菌群結(jié)構(gòu)、影響膽汁酸的合成與代謝、上調(diào)低密度脂蛋白受體(LDLR)的表達(dá)、激活內(nèi)臟脂肪組織相關(guān)基因的表達(dá)、升高血清脂聯(lián)素的表達(dá)、激活腺苷酸活化蛋白激酶(AMPK)途徑、改善胰島素抵抗等多個(gè)作用靶點(diǎn)發(fā)揮調(diào)脂作用,主要針對小檗堿的調(diào)脂作用及其機(jī)制進(jìn)行綜述。

Berberine is an isoquinoline alkaloid isolated from Coptis chinensis, and it is applied widely in clinic as a traditional anti-inflammatory and antibacterial drug for a long time. In recent years, it has been discovered that berberine still has lipid-regulating effects. Berberine plays the role of lipid-regulating by adjusting the structure of intestinal flora, influencing the synthesis and metabolism of bile acid, up-regulating the expression of low density lipoprotein receptor (LDLR), activating the expression of visceral adipose tissue related genes, elevating the expression of adiponectin, activating AMP-activated protein kinase (AMPK) pathways, and improving insulin resistance. This paper mainly summarizes the lipid-regulating function of berberine and its mechanisms of action.

"重大新藥創(chuàng)制"科技重大專項(xiàng)(2012ZX09303-008-001);2010年國家臨床重點(diǎn)專科建設(shè)項(xiàng)目